Skip to content

AbbVie ABBV EV / EBITDA

EV / EBITDA at other companies

Eli Lilly logo
Eli LillyLLY
25.9×-24.4×
Pfizer logo
PfizerPFE
12.9×
Johnson & Johnson logo
Johnson & JohnsonJNJ
18.8×+4.2×
Amgen logo
AmgenAMGN
15.9×-1.3×
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
17.2×+0.2×
Cardinal Health logo
Cardinal HealthCAH
16.9×+4.4×

Other financials

Income statement

See full
Revenue$15.0B+12.4%
Gross profit$10.8B+15.4%
Operating income$4.0B+6.9%
Net income$695.0M-46.0%
EPS (diluted)$0.39-45.8%

Balance sheet

See full
Cash & equivalents$9.4B+81.5%
Total debt$62.4B+1.8%
Total equity-$6.7B-569%
Total assets$136.46B+0.2%

Cash flow

See full
Operating cash flow$3.8B+134%
CapEx$265.0M+12.8%
Free cash flow$3.6B+155%

Valuation

See full
Market cap$382.49B+3.8%
P/E105.2×+17.4×
P/S6.1×-0.3×

Profitability

See full
Gross margin70.7%0.0pp
Operating margin24.4%
Net margin5.8%-1.5pp
FCF margin31.8%+5.0pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×0.0×

Where this comes from

Calculated from AbbVie’s reported figures.

Based on the most recent quarter.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbbVie's EV / EBITDA?
AbbVie (ABBV) reported EV / EBITDA of 19.8× in Q4 2025.
What is the long-term trend for AbbVie's EV / EBITDA?
Over 4 years (2020 to 2025), AbbVie's EV / EBITDA has grown at a 8.0% compound annual growth rate (CAGR), from 14.6× to 19.8×.
What does EV / EBITDA mean?
What the whole business (debt included) costs relative to its operating cash earnings.
How do you interpret EV / EBITDA?
Lets you compare companies with different leverage and tax positions on a like-for-like basis — the standard multiple in M&A. Lower can mean cheaper, subject to growth and capital intensity.
How does EV / EBITDA compare across companies?
Broadly comparable across non-financial sectors; not used for banks and insurers, where EBITDA is not meaningful.